This HTML5 document contains 28 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n14https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:HAP
dbo:wikiPageWikiLink
dbr:Hypoxia-activated_prodrug
dbo:wikiPageDisambiguates
dbr:Hypoxia-activated_prodrug
Subject Item
dbr:Hypoxia-activated_prodrug
rdfs:label
Hypoxia-activated prodrug
rdfs:comment
Hypoxia-Activated Prodrugs (HAPs) are prodrugs that target regions of tumor hypoxia within tumor cells. HAPs may offer the potential, alone and in combination with conventional chemotherapy, of improving cancer therapy. It is believed that tumor hypoxia contributes significantly to treatment failure and relapse among cancer patients because cells in the hypoxic zones of solid tumors resist traditional chemotherapy for at least two reasons: first, most antitumor agents cannot penetrate beyond 50-100 micrometers from capillaries, thereby never reaching those cells in the hypoxic regions. Secondly, the lower nutrient and oxygen supply to cells in the hypoxic zones of tumors cause them to divide more slowly than their well oxygenated counterparts, so hypoxic tumor cells exhibit greater resista
dcterms:subject
dbc:Oxygen
dbo:wikiPageID
18216135
dbo:wikiPageRevisionID
1074455197
dbo:wikiPageWikiLink
dbr:TH-302 dbr:Prodrug dbr:AQ4N dbr:Phenotypes dbc:Oxygen dbr:PR-104 dbr:Tumor_hypoxia
owl:sameAs
wikidata:Q5961513 yago-res:Hypoxia-activated_prodrug n14:4ndBB
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Cn
dbo:abstract
Hypoxia-Activated Prodrugs (HAPs) are prodrugs that target regions of tumor hypoxia within tumor cells. HAPs may offer the potential, alone and in combination with conventional chemotherapy, of improving cancer therapy. It is believed that tumor hypoxia contributes significantly to treatment failure and relapse among cancer patients because cells in the hypoxic zones of solid tumors resist traditional chemotherapy for at least two reasons: first, most antitumor agents cannot penetrate beyond 50-100 micrometers from capillaries, thereby never reaching those cells in the hypoxic regions. Secondly, the lower nutrient and oxygen supply to cells in the hypoxic zones of tumors cause them to divide more slowly than their well oxygenated counterparts, so hypoxic tumor cells exhibit greater resistance to chemotherapies and radiation which target rapidly dividing cells or require oxygen for efficacy. Hypoxia also contributes to the invasive and metastatic phenotypes of aggressive cancers by promoting genetic instability and accelerating the accumulation of mutations that can ultimately give rise to drug resistance. There are several companies developing HAPs: Novacea, Inc. (acquired by Transcept/Paratek pharmaceuticals), Proacta Inc. (now defunct) and Threshold Pharmaceuticals, Inc. These companies are involved in developing the following drug candidates: (Novacea), PR-104 (Proacta) and TH-302 (evofosfamide) and TH-4000 (tarloxotinib) (Threshold Pharmaceuticals).
prov:wasDerivedFrom
wikipedia-en:Hypoxia-activated_prodrug?oldid=1074455197&ns=0
dbo:wikiPageLength
3429
foaf:isPrimaryTopicOf
wikipedia-en:Hypoxia-activated_prodrug
Subject Item
dbr:Hypoxia-activated_prodrugs
dbo:wikiPageWikiLink
dbr:Hypoxia-activated_prodrug
dbo:wikiPageRedirects
dbr:Hypoxia-activated_prodrug
Subject Item
dbr:Hypoxia_activated_prodrugs
dbo:wikiPageWikiLink
dbr:Hypoxia-activated_prodrug
dbo:wikiPageRedirects
dbr:Hypoxia-activated_prodrug
Subject Item
wikipedia-en:Hypoxia-activated_prodrug
foaf:primaryTopic
dbr:Hypoxia-activated_prodrug